Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients

Conclusions: p95HER2-positive CTCs can be detected in both early and metastatic breast cancer patients. Their incidence is increased in the metastatic setting and their presence is associated with poor survival. Longitudinal studies during anti-HER2 treatment are required to determine the clinical relevance of p95HER2-expressing CTCs.
Source: Breast Cancer Research - Category: Cancer & Oncology Authors: Source Type: research